---
input_text: In Vivo Intracerebral Administration of alpha-Ketoisocaproic Acid to Neonate
  Rats Disrupts Brain Redox Homeostasis and Promotes Neuronal Death, Glial Reactivity,
  and Myelination Injury. Maple syrup urine disease (MSUD) is caused by severe deficiency
  of branched-chain alpha-keto acid dehydrogenase complex activity, resulting in tissue
  accumulation of branched-chain alpha-keto acids and amino acids, particularly alpha-ketoisocaproic
  acid (KIC) and leucine. Affected patients regularly manifest with acute episodes
  of encephalopathy including seizures, coma, and potentially fatal brain edema during
  the newborn period. The present work investigated the ex vivo effects of a single
  intracerebroventricular injection of KIC to neonate rats on redox homeostasis and
  neurochemical markers of neuronal viability (neuronal nuclear protein (NeuN)), astrogliosis
  (glial fibrillary acidic protein (GFAP)), and myelination (myelin basic protein
  (MBP) and 2',3'-cyclic-nucleotide 3'-phosphodiesterase (CNPase)) in the cerebral
  cortex and striatum. KIC significantly disturbed redox homeostasis in these brain
  structures 6 h after injection, as observed by increased 2',7'-dichlorofluorescein
  oxidation (reactive oxygen species generation), malondialdehyde levels (lipid oxidative
  damage), and carbonyl formation (protein oxidative damage), besides impairing the
  antioxidant defenses (diminished levels of reduced glutathione and altered glutathione
  peroxidase, glutathione reductase, and superoxide dismutase activities) in both
  cerebral structures. Noteworthy, the antioxidants N-acetylcysteine and melatonin
  attenuated or normalized most of the KIC-induced effects on redox homeostasis. Furthermore,
  a reduction of NeuN, MBP, and CNPase, and an increase of GFAP levels were observed
  at postnatal day 15, suggesting neuronal loss, myelination injury, and astrocyte
  reactivity, respectively. Our data indicate that disruption of redox homeostasis,
  associated with neural damage caused by acute intracerebral accumulation of KIC
  in the neonatal period may contribute to the neuropathology characteristic of MSUD
  patients.
raw_completion_output: |-
  primary_disease: Maple syrup urine disease (MSUD)

  medical_actions: Intracerebral administration of alpha-Ketoisocaproic Acid (KIC); Ex vivo investigation; Antioxidants administration (N-acetylcysteine, melatonin)

  symptoms: Seizures; Coma; Brain edema; Disruption of redox homeostasis; Neuronal death; Glial reactivity; Myelination injury

  chemicals: alpha-Ketoisocaproic Acid (KIC); Leucine; N-acetylcysteine; Melatonin; 2',7'-dichlorofluorescein; Malondialdehyde; Reduced glutathione; Glutathione peroxidase; Glutathione reductase; Superoxide dismutase

  action_annotation_relationships: Intracerebral administration of alpha-Ketoisocaproic Acid (KIC) PROMOTES Disruption of redox homeostasis IN Maple syrup urine disease (MSUD); Intracerebral administration of alpha-Ketoisocaproic Acid (KIC) PROMOTES Neuronal death IN Maple syrup urine disease (MSUD); Intracerebral administration of alpha-Ketoisocaproic Acid (KIC) PROMOTES Glial reactivity IN Maple syrup urine disease (MSUD); Intracerebral administration of alpha-Ketoisocaproic Acid (KIC) PROMOTES Myelination injury IN Maple syrup urine disease (MSUD); Antioxidants administration (N-acetylcysteine, melatonin) TREATS Disruption of redox homeostasis IN Maple syrup urine disease (MSUD)
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  Antioxidants administration (N-acetylcysteine, melatonin) TREATS Disruption of redox homeostasis IN Maple syrup urine disease (MSUD)

  ===

extracted_object:
  primary_disease: MONDO:0009563
  medical_actions:
    - Intracerebral administration of alpha-Ketoisocaproic Acid (KIC)
    - Ex vivo investigation
    - Antioxidants administration (N-acetylcysteine, melatonin)
  symptoms:
    - HP:0001250
    - HP:0001259
    - HP:0002181
    - Disruption of redox homeostasis
    - Neuronal death
    - Glial reactivity
    - Myelination injury
  chemicals:
    - CHEBI:48430
    - CHEBI:25017
    - CHEBI:28939
    - CHEBI:16796
    - CHEBI:51596
    - CHEBI:566274
    - CHEBI:16856
    - Glutathione peroxidase
    - Glutathione reductase
    - Superoxide dismutase
  action_annotation_relationships:
    - subject: Intracerebral administration
      predicate: PROMOTES
      object: Disruption of redox homeostasis
      qualifier: MONDO:0009563
      subject_extension: CHEBI:48430
    - subject: Intracerebral administration
      predicate: PROMOTES
      object: Neuronal death
      qualifier: MONDO:0009563
      subject_extension: CHEBI:48430
    - subject: Intracerebral administration
      predicate: PROMOTES
      object: Glial reactivity
      qualifier: MONDO:0009563
      subject_extension: CHEBI:48430
    - subject: Intracerebral administration
      predicate: PROMOTES
      object: Myelination injury
      qualifier: MONDO:0009563
      subject_extension: CHEBI:48430
    - subject: Antioxidants administration
      predicate: TREATS
      object: Disruption of redox homeostasis
      qualifier: MONDO:0009563
      subject_extension: N-acetylcysteine, melatonin
named_entities:
  - id: MONDO:0009563
    label: Maple syrup urine disease (MSUD)
  - id: CHEBI:25017
    label: Leucine
  - id: CHEBI:22359
    label: alloisoleucine (allo-ile)
  - id: HP:0100626
    label: End stage liver diseases
  - id: MONDO:0100193
    label: End stage liver diseases
  - id: MONDO:0019052
    label: Inborn errors of metabolism
  - id: MAXO:0000603
    label: Peritoneal dialysis
  - id: MAXO:0001175
    label: Liver transplantation (LT)
  - id: MAXO:0009003
    label: Preimplantation genetic testing (PGT)
  - id: CHEBI:24898
    label: isoleucine
  - id: CHEBI:27266
    label: valine
  - id: MAXO:0000088
    label: diet
  - id: HP:0001263
    label: mental and motor retardation
  - id: HP:0002098
    label: respiratory distress
  - id: MONDO:0008143
    label: Organic Acidemias (OAs)
  - id: MONDO:0000688
    label: Organic Acidemias
  - id: MONDO:0021055
    label: Familial amyloidotic polyneuropathy (FAP)
  - id: HP:0003159
    label: hyperoxaluria
  - id: MONDO:0002474
    label: primary hyperoxaluria
  - id: MONDO:0008294
    label: acute intermittent porphyria
  - id: HP:0011034
    label: Amyloidosis
  - id: HP:0011968
    label: Poor feeding
  - id: HP:0001259
    label: Coma
  - id: HP:0001252
    label: Hypotonia
  - id: HP:0002013
    label: vomiting
  - id: HP:0000737
    label: irritability
  - id: HP:0003256
    label: Coagulopathy
  - id: HP:0001993
    label: Ketoacidosis
  - id: HP:0001251
    label: Ataxia
  - id: MONDO:0017052
    label: intermediate maple syrup urine disease (iMSUD)
  - id: MAXO:0001525
    label: Intravenous administration
  - id: CHEBI:17895
    label: Tyr
  - id: CHEBI:16828
    label: Trp
  - id: CHEBI:141437
    label: His
  - id: CHEBI:16044
    label: Met
  - id: CHEBI:16857
    label: Thr
  - id: CHEBI:30011
    label: Gln
  - id: CHEBI:17295
    label: Phe
  - id: CHEBI:28300
    label: glutamine
  - id: CHEBI:16449
    label: alanine
  - id: CHEBI:27363
    label: zinc
  - id: CHEBI:27568
    label: selenium
  - id: CHEBI:27432
    label: alpha-linolenic acid (18:3n-3)
  - id: CHEBI:36005
    label: docosahexaenoic acid (22:6n-3)
  - id: CHEBI:17865
    label: Alpha-ketoisocaproate (KIC)
  - id: HP:0003811
    label: Neonatal death
  - id: HP:0001873
    label: thrombocytopenia
  - id: HP:0002615
    label: hypotension
  - id: HP:0002901
    label: hypocalcemia
  - id: HP:0001942
    label: metabolic acidosis
  - id: CHEBI:145810
    label: Insulin
  - id: MONDO:0008867
    label: biliary atresia
  - id: CHEBI:48430
    label: Alpha-ketoisocaproic acid (KIC)
  - id: MAXO:0000600
    label: renal replacement therapy (RRT)
  - id: MAXO:0000601
    label: dialysis
  - id: CHEBI:15603
    label: amino-acid mixture without leucine (Leu), valine, isoleucine
  - id: MAXO:0001495
    label: parenteral administration
  - id: MAXO:0000943
    label: Dried blood spot (DBS) monitoring
  - id: CHEBI:22918
    label: Branched-chain amino acids (BCAA)
  - id: CHEBI:33349
    label: <Dried blood spot (DBS)>
  - id: MONDO:0009949
    label: PC deficiency
  - id: HP:0001977
    label: abnormal blood clotting
  - id: HP:0000717
    label: Autism
  - id: HP:0001249
    label: Intellectual disability
  - id: HP:0001250
    label: Seizures
  - id: MONDO:0004739
    label: <Urea cycle defects (UCD), organic acidemias (OA), maple syrup urine disease
      (MSUD)>
  - id: HP:0001987
    label: elevated ammonia levels
  - id: CHEBI:29987
    label: Glutamate
  - id: CHEBI:21547
    label: N-acetylaspartate (NAA)
  - id: CHEBI:16919
    label: Creatine
  - id: HP:0006846
    label: acute encephalopathy
  - id: HP:0033667
    label: mental impairment (IQ <= 70)
  - id: HP:0001943
    label: Hypoglycemia
  - id: HP:0001257
    label: Spasticity
  - id: HP:0000988
    label: Rash
  - id: HP:0001876
    label: Pancytopenia
  - id: HP:0001919
    label: Acute kidney injury
  - id: HP:0030005
    label: Capillary leak syndrome
  - id: CHEBI:176838
    label: Riboflavin (vitamin B2)
  - id: CHEBI:176841
    label: Biotin (vitamin B7)
  - id: HP:0002878
    label: respiratory failure
  - id: HP:0010911
    label: Hyperleucinemia
  - id: MAXO:0001001
    label: gene therapy
  - id: HP:0000938
    label: osteopenia
  - id: CHEBI:28938
    label: ammonia
  - id: CHEBI:30860
    label: methylmalonic acid
  - id: CHEBI:15702
    label: Tissue plasminogen activator (tPA)
  - id: HP:0001699
    label: sudden death
  - id: MAXO:0000932
    label: Electroencephalography
  - id: HP:0001298
    label: Encephalopathy
  - id: HP:0002586
    label: peritonitis
  - id: HP:0003774
    label: chronic renal failure
  - id: MONDO:0008723
    label: Very-long chain acyl-CoA dehydrogenase deficiency (VLCAD)
  - id: CHEBI:17453
    label: methylmalonate
  - id: MONDO:0002012
    label: Methylmalonic Acidemia
  - id: MONDO:0008815
    label: Argininosuccinic Aciduria (ASA)
  - id: MAXO:0000602
    label: Hemodialysis (HD)
  - id: HP:0002344
    label: Neurologic deterioration
  - id: MONDO:0007100
    label: Familial Amyloid Polyneuropathy
  - id: MONDO:0005439
    label: Familial Hypercholesterolemia
  - id: HP:0002181
    label: Brain swelling
  - id: HP:0034254
    label: Face of the Giant Panda Sign
  - id: MAXO:0000112
    label: Antioxidant therapies
  - id: HP:0025464
    label: Oxidative stress
  - id: MAXO:0000917
    label: Stenting
  - id: HP:0030242
    label: Portal vein thrombosis
  - id: CHEBI:28939
    label: N-acetylcysteine
  - id: CHEBI:16796
    label: Melatonin
  - id: CHEBI:51596
    label: 2',7'-dichlorofluorescein
  - id: CHEBI:566274
    label: Malondialdehyde
  - id: CHEBI:16856
    label: Reduced glutathione
